CAPABILITY OVERVIEW
MayMag Biologics — CDMO Media Kit
For CDMO directory submissions, trade publication pitches, and partnership enquiries.
Company at a Glance
Regulatory status
FDA Section 506(e) outsourcing facility
Facilities
Dallas, TX and Garland, TX — GMP-certified
Core capability
Peptide synthesis, sterile fill-finish, biosimilars
Distribution model
Commercial — distributors & healthcare systems
About MayMag Biologics
MayMag Biologics is a US-based 506(e) pharmaceutical manufacturer and CDMO operating from GMP-certified facilities in Dallas and Garland, Texas. The company provides large-scale biosimilar compounding, sterile injectable manufacturing, and GLP-1 receptor agonist peptide synthesis for commercial distributors and healthcare systems — without the patient-prescription constraints of 503A/503B compounding models.
As a domestic alternative to European and Asian CDMOs, MayMag Biologics addresses the supply chain resilience gap for US hospitals, integrated delivery networks, and specialty pharmaceutical distributors seeking reliable, GMP-grade domestic supply of tirzepatide analogues, insulin biosimilars, and sterile injectables.
Core Manufacturing Capabilities
506(e) Large-Scale Compounding
Commercial-scale biosimilar and sterile injectable production for pharmaceutical distributors and healthcare systems. No patient-specific prescription required. GMP-certified, state and federal regulatory oversight.
GLP-1 Peptide Synthesis
GMP-grade solid-phase peptide synthesis (SPPS) of tirzepatide analogues, semaglutide analogues, and other GLP-1/GIP receptor agonists at commercial scale. Full analytical characterisation including HPLC, MS, endotoxin, and sterility.
Aseptic Fill-Finish
ISO 5 (Class 100) cleanroom fill-finish for sterile injectables. Lyophilisation with validated cycle development. Container closure integrity testing. Prefilled pens, vials, and autoinjector formats.
Biosimilar Insulin Manufacturing
Insulin biosimilar pen systems for supply chain redundancy. Prefilled pen format. Designed for hospital formulary and IDN procurement programmes seeking domestic supply alternatives.
Inhalation Therapeutics
MDI and DPI formulation development and manufacturing for respiratory therapeutics. Full development-to-commercial manufacturing capability.
Autoinjector Platform
Proprietary anti-inflammatory autopen for rheumatoid arthritis and inflammatory conditions. Prefilled, single-use format. CDMO/CMO manufacturing for FDA short-listed sterile RA generics including adalimumab and etanercept biosimilars.
Bacteriostatic Water for Injection
Large-scale sterile bacteriostatic water (0.9% benzyl alcohol) for peptide reconstitution. Commercial volumes for distributor supply.
Oligonucleotide Synthesis
GMP-grade oligonucleotide synthesis for antisense and siRNA therapeutic applications.
Competitive Positioning
How MayMag Biologics compares to global CDMO alternatives for US pharmaceutical distributors.
| Factor | MayMag Biologics | Bachem | PolyPeptide Group | WuXi AppTec |
|---|---|---|---|---|
| Regulatory model | 506(e) — US commercial distribution | GMP API manufacturer (EU) | GMP API manufacturer (EU/US) | GMP CDMO (China/US) |
| Geography | Dallas & Garland, Texas | Switzerland / US | Sweden / US | China / US |
| Min. order qty | Commercial scale, flexible | Kilogram-scale minimums | Kilogram-scale minimums | Kilogram-scale minimums |
| Lead time | Domestic — weeks | International — months | International — months | International — months |
| GLP-1 biosimilars | ✓ Tirzepatide, semaglutide | ✓ API only | ✓ API only | ✓ API only |
| Aseptic fill-finish | ✓ In-house ISO 5 | ✗ API only | ✗ API only | ✓ Some sites |
| 506(e) distribution | ✓ Commercial distributors | ✗ | ✗ | ✗ |
Available Guest Post Topics
MayMag Biologics subject matter experts are available to contribute articles on the following topics to trade publications and industry platforms.
506(e) Manufacturing Requirements
How Section 506(e) differs from 503A/503B, what it enables for commercial distribution, and why it matters for US biosimilar supply chain resilience.
Tirzepatide CDMO Capabilities
The synthesis complexity of 39-residue GLP-1/GIP dual agonists, what separates capable CDMOs from inadequate ones, and the case for domestic US production.
Peptide Synthesis Quality Standards
GMP SPPS from resin selection through aseptic fill-finish — the analytical package, documentation requirements, and what distinguishes pharmaceutical-grade from research-grade peptides.
US Biosimilar Supply Chain Resilience
Why geographic concentration of biosimilar API manufacturing in Europe and Asia creates systemic risk for US healthcare systems, and how domestic 506(e) manufacturers address it.
Custom vs. Off-the-Shelf Peptide Supply
Decision framework for procurement teams evaluating catalogue suppliers versus custom GMP manufacturing — regulatory requirements, volume thresholds, and supply chain ownership.
GLP-1 Drug Shortage: Lessons and Solutions
What the 2023–2024 GLP-1 shortage revealed about US pharmaceutical supply chain vulnerabilities and the structural changes needed to prevent recurrence.
Ready to Pitch or Partner?
For guest post pitches, directory submissions, or CDMO partnership enquiries, contact our press team directly.